Repaglinide Tablet
NDC 62135-948
Product Information
Repaglinide is a ANDA-approved product labeled by Chartwell Rx, Llc. Repaglinide is used alone or with other medications to control high blood sugar along with a proper diet and exercise program. It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 62135-948 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
YELLOW (C48330 - YELLOW TO PALE YELLOW)
OVAL (C48345)
8 MM
CE;251
CE;252
CE;253
Code Structure Chart
Product Details
What is NDC 62135-948?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- REPAGLINIDE (UNII: 668Z8C33LU)
- REPAGLINIDE (UNII: 668Z8C33LU) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- STARCH, CORN (UNII: O8232NY3SJ)
- DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP)
- GLYCERIN (UNII: PDC6A3C0OX)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MEGLUMINE (UNII: 6HG8UB2MUY)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- POLOXAMER 188 (UNII: LQA7B6G8JG)
- POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)
- POLACRILIN POTASSIUM (UNII: 0BZ5A00FQU)
- TALC (UNII: 7SEV7J4R1U)
- FERRIC OXIDE YELLOW (UNII: EX438O2MRT)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 200256 - repaglinide 1 MG Oral Tablet
- RxCUI: 200257 - repaglinide 0.5 MG Oral Tablet
- RxCUI: 200258 - repaglinide 2 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.